- PD-L1: PD-L1 expression in the macrophage compartment was associated with progression-free survival and overall survival in NSCLC. PD-L1 expression in the macrophage compartment was also associated with immune therapy response in NSCLC.
- CD45RO: CD45RO expression in the CD45+ immune cell infiltrate correlated with ICPI response.
- B2M: B2M expression in the tumor and stroma compartment was correlated with longer overall survival to anti-PD-1 therapy.
- CD3: CD3 expression in the tumor and stroma compartment was associated with progression-free survival and overall survival.
- CD8: CD8 expression in the CD45+ immune cell infiltrate correlated with ICPI response.
- CD19: CD19 expression in the CD45+ immune cell infiltrate correlated with ICPI response.
- CD20: CD20 expression in the CD45+ immune cell infiltrate correlated with ICPI response.
- Ki67: Ki67 expression in the CD45+ immune cell infiltrate correlated with ICPI response.
- CD19: CD19 expression was associated with improved overall survival in NSCLC.
- CD20: CD20 expression was associated with improved overall survival in NSCLC.
- CD34: CD34 expression in the tumor compartment was associated with improved overall survival in NSCLC.
- CD45: CD45 expression was associated with progressive disease during ICPI treatment.
- CD44: CD44 expression was correlated with progressive disease during ICPI treatment.
- CD66b: CD66b expression was correlated with progressive disease during ICPI treatment.
- CD68: CD68 expression was correlated with progressive disease during ICPI treatment.
- CD4: CD4 expression was associated with overall survival, progression-free survival, and durable benefit in NSCLC.
- CD56: CD56 expression was associated with overall survival, progression-free survival, and durable benefit in NSCLC.
- CD4: CD4 expression was associated with poorer progression-free survival and overall survival.
- LAG3: LAG3 expression was associated with poorer progression-free survival and overall survival.
- CD3: CD3 expression was associated with improved overall survival in NSCLC.
- ICOS: ICOS expression was associated with improved overall survival in NSCLC.
- CD34: CD34 expression was associated with improved overall survival in NSCLC.
- CD45: CD45 expression was associated with improved overall survival in NSCLC.
- CD19: CD19 expression was associated with improved overall survival in NSCLC.
- CD20: CD20 expression was associated with improved overall survival in NSCLC.
- Ki67: Ki67 expression was associated with improved overall survival in NSCLC.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD4: CD4 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was not predictive for the ICPI treatment outcome.
- CD4: CD4 expression was associated with progressive disease.
- CD45RO: CD45RO expression was associated with progressive disease.
- CD68: CD68 expression was associated with progressive disease.
- IDO-1: IDO-1 expression was associated with progressive disease.
- P-ERK: P-ERK expression was associated with progressive disease.
- Ki67: Ki67 expression was associated with progressive disease.
- PD-L1: PD-L1 expression was associated with progressive disease.
- PD-1: PD-1 expression was associated with progressive disease.
- Granzyme B: Granzyme B expression was associated with progressive disease.
- CD45: CD45 expression was associated with progressive disease.
- OX40: OX40 expression was associated with progressive disease.
- STAT3: STAT3 expression was associated with progressive disease.
- P-STAT3: P-STAT3 expression was associated with progressive disease.
- CD44: CD44 expression was associated with progressive disease.
- STING: STING expression was associated with progressive disease.
- CD66b: CD66b expression was associated with progressive disease.
- P-AKT: P-AKT expression was associated with progressive disease.
- PTEN: PTEN expression was associated with progressive disease.
- CD56: CD56 expression was associated with longer progression-free survival, prolonged overall survival, and durable benefit.
- CD4: CD4 expression was associated with longer progression-free survival, prolonged overall survival, and durable benefit.
- VISTA: VISTA expression was associated with non-durable benefit and shorter progression-free survival.
- CD127: CD127 expression was associated with non-durable benefit and shorter progression-free survival.
- CD3: CD3 expression was associated with improved overall survival.
- ICOS: ICOS expression was associated with improved overall survival.
- CD34: CD34 expression was associated with improved overall survival.
- CD45: CD45 expression was associated with improved overall survival.
- CD19: CD19 expression was associated with improved overall survival.
- CD20: CD20 expression was associated with improved overall survival.
- Ki67: Ki67 expression was associated with improved overall survival.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD4: CD4 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD8: CD8 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD19: CD19 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD20: CD20 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- Ki67: Ki67 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD45RO: CD45RO expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- B2M: B2M expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- CD3: CD3 expression was associated with relapse after adjuvant or neoadjuvant ipilimumab and nivolumab.
- PD-L1: PD-L1 expression was associated with relapse after
